| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2002 | WO2002012189A1 Fused bicyclic amide compounds and medicinal use thereof |
| 02/14/2002 | WO2002012188A2 Indole compounds useful for the treatment of cancer |
| 02/14/2002 | WO2002012181A1 Novel diamines having a casr modulating activity |
| 02/14/2002 | WO2002012178A1 Compounds acting as melanocortin receptor ligands |
| 02/14/2002 | WO2002012177A1 Composition of metformin with succinic acid or salts thereof and method for treating diabetes |
| 02/14/2002 | WO2002012168A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 02/14/2002 | WO2002011803A1 Electro-powder |
| 02/14/2002 | WO2002011779A1 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 02/14/2002 | WO2002011778A1 System and method for intranasal administration of opioids |
| 02/14/2002 | WO2002011770A1 Compositions for preventing urinary calculus |
| 02/14/2002 | WO2002011766A2 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 02/14/2002 | WO2002011765A1 COMBINATION PREPARATION WITH AN ERβ SELECTIVE ESTROGEN AND A SERM OR ANTIESTROGEN |
| 02/14/2002 | WO2002011764A2 Pharmaceutical compositions |
| 02/14/2002 | WO2002011763A1 Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| 02/14/2002 | WO2002011751A2 Combinations of dalfopristine/quinupristine with cefpirome |
| 02/14/2002 | WO2002011750A2 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway |
| 02/14/2002 | WO2002011746A2 Chlorella preparations exhibiting immunomodulating properties |
| 02/14/2002 | WO2002011744A1 A strong antioxidant composite capsule containing grape seed extract opc and process for producing the same |
| 02/14/2002 | WO2002011743A2 Treatment of prostate cancer |
| 02/14/2002 | WO2002011741A1 Cardioplegic solution |
| 02/14/2002 | WO2002011739A1 Methods for preventing pressure induced apoptotic neural cell death |
| 02/14/2002 | WO2002011738A1 Cosmetics or dermatological preparations containing polymers having phosphorylcholine side chain |
| 02/14/2002 | WO2002011737A2 Anti-inflammatory medicament |
| 02/14/2002 | WO2002011736A1 Naadp analogues for modulating t-cell activity |
| 02/14/2002 | WO2002011735A2 Association of a purine activity and a nonsteroidal anti-inflammatory anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011733A1 Pharmaceutical composition comprising condensed indole compound |
| 02/14/2002 | WO2002011732A1 Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists |
| 02/14/2002 | WO2002011731A2 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches |
| 02/14/2002 | WO2002011730A1 Radiosensitising agent for curing oncological diseases |
| 02/14/2002 | WO2002011729A1 Novel compositions and methods for treatment of male erectile dysfunction |
| 02/14/2002 | WO2002011728A2 Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/14/2002 | WO2002011727A1 Stable pergolide mesylate and process for making same |
| 02/14/2002 | WO2002011726A1 Highly absorbable solid preparation |
| 02/14/2002 | WO2002011725A1 Inflammatory cytokine production inhibitors |
| 02/14/2002 | WO2002011724A2 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | WO2002011723A1 Synergistic effect of amlodipine and atorvastatin |
| 02/14/2002 | WO2002011722A1 Substituted and non-substituted benzooxathiazoles and compounds derived therefrom |
| 02/14/2002 | WO2002011721A1 Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative |
| 02/14/2002 | WO2002011720A1 Processes for the purification of tocopherol and/or sterol compounds and compositions containing orthoborate ester mixtures |
| 02/14/2002 | WO2002011719A2 Lipase inhibitors for the treatment of dyspepsia |
| 02/14/2002 | WO2002011718A1 IgE PRODUCTION INHIBITORS |
| 02/14/2002 | WO2002011717A1 Cosmetics to support skin metabolism |
| 02/14/2002 | WO2002011716A2 Liquid formulation of metformin |
| 02/14/2002 | WO2002011715A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | WO2002011714A2 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 02/14/2002 | WO2002011713A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 02/14/2002 | WO2002011712A2 Combination of huperzine and nicotinic compounds as a neuroprotective agent |
| 02/14/2002 | WO2002011711A2 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 02/14/2002 | WO2002011710A2 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | WO2002011709A2 Pharmaceutical, effervescent formulation containing ramipril |
| 02/14/2002 | WO2002011708A2 Methods for inducing apolipoprotein e secretion |
| 02/14/2002 | WO2002011707A2 Drugs for incontinence |
| 02/14/2002 | WO2002011706A2 Drugs for sex dysfunctions |
| 02/14/2002 | WO2002011705A2 Composition for combined use of aromatase inhibitors |
| 02/14/2002 | WO2002011704A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 02/14/2002 | WO2002011702A2 Hydrogel-driven drug dosage form |
| 02/14/2002 | WO2002011700A1 Analgesic, anti-inflammatory and skeletal muscle relaxant compositions |
| 02/14/2002 | WO2002011698A1 Novel compositions of minoxidil |
| 02/14/2002 | WO2002011697A1 A method of preparing a pharmaceutical composition |
| 02/14/2002 | WO2002011694A2 Compositions and dosage forms for application in the oral cavity in the treatment of mykoses |
| 02/14/2002 | WO2002011683A1 Topical gel delivery system |
| 02/14/2002 | WO2002011677A2 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | WO2002011676A2 Method of using diketopiperazines and composition containing them |
| 02/14/2002 | WO2002011670A2 Solid forms of tin ethyl etiopurpurin and processes for producing such forms |
| 02/14/2002 | WO2002011668A2 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients |
| 02/14/2002 | WO2002011665A2 Association of a purine and a nonsteroidal anti-inflammatory drug for treating sexual dysfunction |
| 02/14/2002 | WO2002011563A1 Food supplement |
| 02/14/2002 | WO2002011551A2 Oil/fat composition |
| 02/14/2002 | WO2002011550A2 Oil/fat composition |
| 02/14/2002 | WO2002011539A1 Methods and compositions for treating skin ulcers by topical photodynamic therapy |
| 02/14/2002 | WO2002005844A8 Protein complex serving as a vehicle for orally administerable medicaments |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001076531A3 Bile acid containing prodrugs with enhanced bioavailability |
| 02/14/2002 | WO2001072264A3 Pro-liposomal encapsulated preparations (iv) |
| 02/14/2002 | WO2001068663B1 Nucleoside compounds and uses thereof |
| 02/14/2002 | WO2001068603A3 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 02/14/2002 | WO2001066115A3 Acetylsalicylic acid solutions |
| 02/14/2002 | WO2001064247A3 Method of treating cancer with anti-neurotrophin agents |
| 02/14/2002 | WO2001062954A8 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| 02/14/2002 | WO2001059120A3 Il-17 like molecules and uses thereof |
| 02/14/2002 | WO2001058951A3 Water-soluble ligand-binding proteins of ligand-gated ion channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 02/14/2002 | WO2001058921A3 Methods and compositions for generating angiostatin |
| 02/14/2002 | WO2001058915A3 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 02/14/2002 | WO2001055119A3 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 02/14/2002 | WO2001055092A3 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 02/14/2002 | WO2001054679A3 Transdermal composition containing an anesthetic and a vasodilator agent |
| 02/14/2002 | WO2001054675A3 Pharmaceutical compositions comprising terbinafine |
| 02/14/2002 | WO2001051479A3 Tricyclic compounds with antiviral activity |
| 02/14/2002 | WO2001049685A3 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 02/14/2002 | WO2001048161A3 Human heparanase-related polypeptide and nucleic acid |
| 02/14/2002 | WO2001044489A3 Galactomannan oligosaccharides and methods for the production and use thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041807A3 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 02/14/2002 | WO2001041750A3 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 02/14/2002 | WO2001041742A3 Antiviral medication |
| 02/14/2002 | WO2001036973A3 Method for solubilising optical markers |
| 02/14/2002 | WO2001035938A3 Pharmacologically active tetrahydro thiopyran-4-ol derivatives, method for their production and use thereof |
| 02/14/2002 | WO2001034137A3 Oncolytic combinations for the treatment of cancer |
| 02/14/2002 | WO2001034088A3 Cardiac device for electrical and chemical regulation, and vasoactive intestinal peptide for treatment of cardiopulmonary disorders |
| 02/14/2002 | WO2001030802A3 Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |